Patients with CHD-both cyanotic and acyanotic-have variable degrees of increased liability for both thrombosis and hemorrhage that represents some sort of adaptation to preserve hemostasis and to protect these patients against the clinical presentation of both thrombosis and bleeding. This is to say that CHD patients have their own point of balance between thrombogenicity and bleeding liability. Wide-scale studies are needed to detect the normal levels of different thrombohemorrhagic parameters of these patients.

996 The incidence of agranulocytosis during deferiprone (Ferriprox®) use has been reported in clinical trials where patients' neutrophil counts were generally monitored weekly and deferiprone was discontinued at the first sign of neutropenia (neutrophil count < 1.5 × 10 9/L), but the incidence in a less rigorously monitored environment is unknown. This observational, open label, prospective, multi-centre, non-interventional drug surveillance program was designed to assess how the safety of deferiprone therapy is monitored in clinical practice. All patients in the 15 participating treatment sites (Egypt, Oman, Saudi Arabia and Turkey) who initiated therapy with deferiprone during the observation period, were enrolled in the program. There were no exclusion criteria. The program was approved by local ethics boards and informed consent was obtained. 294 patients (53.4% males) were enrolled and the results of the first year of treatment are reported herein. Mean (SD) age of all patients was 12.2 ± 10.1 years (range 1 to 52 years old). 224 (76%) were children (93 of which were 1–5 years; 83 were 6–11 years and 48 were 12–17 years old). The majority of the patients had a diagnosis of Thalassemia Major (N= 261). The other patients had Thalassemia Intermedia (N=17), Sickle Cell Disease (N=9), Spherocytosis (N=3), Red Cell Aplasia/Diamond Blackfan Anemia (N=2), Immune Hemolytic Anemia (N=1) or Sideroblastic Anemia (N=1). Deferiprone was initiated as monotherapy (20 to 100 mg/kg/day) in 247 patients or added to deferoxamine therapy in 41 patients or to deferasirox in 6 patients. Serum ferritin was the common measure of iron overload in all 294 patients. Measurement of cardiac (CIC) and liver iron content (LIC) were conducted within 1 year prior to enrollment in 16 patients. Frequency of those measurements and the technique for those assessments varied among participating centers. CIC and LIC were assessed in 14 patients during the first year of follow up. At completion of 1 year of observation, the mean serum ferritin of the 282 patients who had a baseline and at least one follow up assessment had declined from 2858 ± 2481 to 2454 ± 2074 μg/L (p<0.0001). Monitoring of the neutrophil count was conducted at an average interval of 5 ± 4 weeks (1 week to 6 months). One patient (0.3%) experienced agranulocytosis, which resolved with G-CSF 8 days after discontinuation of deferiprone. Ten patients (3.4%) experienced neutropenia (neutrophil count <1.5 × 109/L but not <0.5 × 109/L). One neutropenia was related to acute myeloid leukemia (AML). Deferiprone therapy was interrupted at diagnosis of AML, considered not related to DFP; and the patient was withdrawn from the program. Two patients had two episodes of neutropenia. All neutropenias, except the one associated with AML, resolved within 51 ± 48 days (range 8 to 167 days). Deferiprone therapy was continued in 7 episodes of neutropenia (time for resolution was 28 ± 24 days (range 8 to 67 days)). Deferiprone was interrupted in the remaining 4 episodes (time for resolution was 93 ± 55 days (range 35 to 167 days). None of the neutropenias progressed to agranulocytosis. The data from this observational study indicate that less frequent monitoring of the neutrophil count and continued deferiprone therapy during neutropenia was not associated with prolonged duration of the neutropenia or progression to agranulocytosis. Further evaluation of this observation is warranted. Disclosures: Elalfy: ApoPharma Inc.: Research Funding. Off Label Use: In USA, FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Shebl:ApoPharma Inc.: Research Funding. Badr:ApoPharma Inc.: Research Funding. Elsafy:ApoPharma Inc.: Research Funding. Salama:ApoPharma Inc.: Research Funding. Al-Tonbary:ApoPharma Inc.: Research Funding. Abdel Rahman:ApoPharma Inc.: Research Funding. Qari:ApoPharma Inc.: Research Funding. Al Damnhouri:ApoPharma Inc.: Research Funding. Al Hawsawi:ApoPharma Inc.: Research Funding. Wali:ApoPharma Inc.: Research Funding. Yesilipek:ApoPharma Inc.: Research Funding. Kilinc:ApoPharma Inc.: Research Funding. Yazman:ApoPharma Inc.: Research Funding. Karakas:ApoPharma Inc.: Research Funding. Tricta:ApoPharma Inc.: Employment.

Background: TORCH infection has a role in aplastic anemia (AA). Fetal hemoglobin may be high in certain acquired hematological conditions such as aplastic anemia. We conducted this study to evaluate the correlation between certain congenital infections and severity of aplastic anemia and to study fetal Hb as a follow up marker during treatment of aplastic anemia. The aim of study was to correlation between certain congenital infection and severity of aplastic anemia and to study of hemoglobin F (HbF) as a follow up marker during treatment of aplastic anemia. Methods: Our prospective study was conducted on 20 children aged up to 18 years diagnosed with aplastic anemia following either bone marrow aspiration or biopsy that proves bone marrow hypocellularity with absence infiltrative BM disease or inherited BM disease recruited from Pediatric Hematology-Oncology Unit of Tanta University Hospital. Patients were classified according to level of HbF in to high HbF group and normal HbF group. Results: TORCH infections were detected in certain numbers of patients . HbF decreased in high HbF group after treatment. There was significant increase in CBC parameters in high HbF group than normal HbF group after treatment. There was insignificant decrease in mortality in high HbF group than normal HbF group. Mild to moderate cases were significantly higher with TORCH IgM +ve cases Conclusions: Acquired AA is associated with TORCH infection. In treated cases of AA, improvement of hematological parameters is associated with high HbF and from these results, it can be used as a prognostic marker to monitor the successful response of these cases to the used line of treatment.